INDEX NAME NOT YET ASSIGNED manufacturers
- FAPI-2
-
- $355.00 / 1mg
-
2024-11-07
- CAS:2370952-98-8
- Min. Order:
- Purity:
- Supply Ability: 10g
- FAPI-2
-
- $355.00 / 1mg
-
2024-11-07
- CAS:2370952-98-8
- Min. Order:
- Purity:
- Supply Ability: 10g
- FAPI-2
-
- $0.00 / 10mg
-
2024-04-02
- CAS:2370952-98-8
- Min. Order: 10mg
- Purity: >95.00%
- Supply Ability: 10mg
|
| | INDEX NAME NOT YET ASSIGNED Basic information |
| | INDEX NAME NOT YET ASSIGNED Chemical Properties |
| Boiling point | 1143.9±65.0 °C(Predicted) | | density | 1.43±0.1 g/cm3(Predicted) | | pka | 1.83±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | INDEX NAME NOT YET ASSIGNED Usage And Synthesis |
| Uses | FAPI-2 is a type of small molecule fibroblast activation protein inhibitor (FAPI) that targets the fibroblast activation protein (FAP) and has an inhibitory effect. This specific targeting ability makes FAPI-2 an effective tumor imaging agent, which can be used in cancer research. FAPI-2 can be used to synthesize 68Ga-FAPI-2 (a PET tracer)[1][2][3][4]. | | References | [1] Giesel FL, et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392. DOI:10.2967/jnumed.118.215913
[2] Moon ES, et al. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging. 2021 Dec 15;11(6):476-491. PMID:35003886
[3] Li M, et al. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2844-2868. doi: 10.1007/s00259-022-05706-y. Epub 2022 Jan 31. Erratum in: Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):3007. DOI:10.1007/s00259-022-05706-y
[4] Sanjana Ballal, et al. First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer. Clin Nucl Med. 2022 Jun 1;47(6):e444-e445. DOI:10.1097/RLU.0000000000004164 |
| | INDEX NAME NOT YET ASSIGNED Preparation Products And Raw materials |
|